MIR5587: A Potential Drug Target and Biomarker (G100847028)

MIR5587: A Potential Drug Target and Biomarker

MIR5587, also known as interleukin-8 (IL-8), is a cytokine that plays a crucial role in the regulation of immune responses and inflammation. It is a small non-coding RNA molecule that is expressed in a variety of tissues and cells, including immune cells, epithelial cells, and cancer cells. MIR5587 has been identified as a potential drug target and biomarker for several diseases, including cancer, autoimmune disorders, and chronic obstructive pulmonary disease (COPD).

The MIR5587 gene was first identified in 2006 and has since been shown to encode a highly conserved cytokine receptor, known as the IL-8 receptor. This receptor is involved in the regulation of immune responses and inflammation, and is a key mediator of both acute and chronic inflammatory responses. MIR5587 has also been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis.

MIR5587 has been shown to be involved in a variety of diseases and conditions, including cancer, autoimmune disorders, and COPD. In cancer, MIR5587 has been shown to be involved in the regulation of immune surveillance, cell cycle progression, and angiogenesis. For example, studies have shown that MIR5587 is expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. It has also been shown to play a role in the regulation of cancer cell survival and the efficacy of anti-cancer drugs.

In autoimmune disorders, MIR5587 has been shown to be involved in the regulation of immune tolerance and the development of autoimmune diseases. For example, studies have shown that MIR5587 is expressed in a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. It has also been shown to play a role in the regulation of autoimmune disease progression and the efficacy of anti-autoimmune drugs.

In addition to its role in disease, MIR5587 has also been shown to be a potential biomarker for several diseases, including cancer, autoimmune disorders, and COPD. For example, studies have shown that MIR5587 can be used as a biomarker for cancer, with researchers finding that MIR5587 is often expressed in cancer tissues and is associated with poor prognosis in cancer patients. It has also been shown to be a potential biomarker for autoimmune disorders, with researchers finding that MIR5587 is often expressed in autoimmune disease tissues and is associated with disease severity.

Furthermore, MIR5587 has also been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, apoptosis, and angiogenesis, and has been implicated in a variety of diseases, including cancer, autoimmune disorders, and COPD. MIR5587 has been shown to play a role in the regulation of TGF-β signaling by regulating the activity of the transcription factor, SMAD.

In conclusion, MIR5587 is a small non-coding RNA molecule that has been shown to play a variety of roles in several diseases, including cancer, autoimmune disorders, and COPD. Its potential as a drug target and biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of MIR5587 in disease and to develop effective treatments for these conditions.

Protein Name: MicroRNA 5587

The "MIR5587 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5587 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR5588 | MIR5589 | MIR559 | MIR5590 | MIR5591 | MIR561 | MIR562 | MIR563 | MIR564 | MIR566 | MIR567 | MIR568 | MIR5680 | MIR5681A | MIR5681B | MIR5682 | MIR5683 | MIR5684 | MIR5685 | MIR5687 | MIR5688 | MIR5689 | MIR569 | MIR5690 | MIR5691 | MIR5692A1 | MIR5692A2 | MIR5692B | MIR5692C1 | MIR5692C2 | MIR5693 | MIR5694 | MIR5695 | MIR5696 | MIR5697 | MIR5698 | MIR5699 | MIR570 | MIR5700 | MIR5701-1 | MIR5701-2 | MIR5701-3 | MIR5702 | MIR5703 | MIR5704 | MIR5705 | MIR5706 | MIR5707 | MIR5708 | MIR570HG | MIR571 | MIR572 | MIR573 | MIR5739 | MIR574 | MIR575 | MIR576 | MIR577 | MIR578 | MIR5787 | MIR579 | MIR580 | MIR581 | MIR582 | MIR583 | MIR584 | MIR585 | MIR586 | MIR587 | MIR588 | MIR589 | MIR590 | MIR591 | MIR592 | MIR593 | MIR595 | MIR596 | MIR597 | MIR598 | MIR599 | MIR600 | MIR600HG | MIR601 | MIR602 | MIR603 | MIR604 | MIR605 | MIR606 | MIR6068 | MIR6069 | MIR607 | MIR6070 | MIR6071 | MIR6072 | MIR6073 | MIR6074 | MIR6075 | MIR6076 | MIR6077 | MIR6078